|drug2739||Quercetin Treatment Wiki||1.00|
|drug1918||MANAGEMENT OF COVID-19 Wiki||1.00|
|D003920||Diabetes Mellitus, NIH||0.20|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that quercetin, as a strong scavenger and anti-inflammatory agent, can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.
Description: Prevalence of COVID-19 in prophylaxis and sham group will be calculated using a questionnaire including hospital recordsMeasure: Prevalence of COVID-19 calculated using a questionnaire Time: 3 months
Description: Mortality rate will be compared between two groupsMeasure: Standardized Mortality rate Time: 3 months
Description: Morbidity rates besides recovery rates from COVID-19 will be documentedMeasure: Morbidity rate Time: 3 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports